Needham analyst Serge Belanger maintained a Buy rating on Heron Therapeutics today and set a price target of $3.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Serge Belanger has given his Buy rating due to a combination of factors tied to Heron Therapeutics’ improving revenue mix and execution. Preliminary fourth quarter 2025 results modestly exceeded expectations, with overall sales growth supported by particularly strong momentum from Zynrelef. The company’s focused commercial strategy around this product—including a dedicated sales force, refinements to its distribution partnership, and the benefit of a recently implemented reimbursement code—has begun to translate into tangible sales acceleration. This improvement helped offset ongoing softness in Heron’s CINV portfolio, signaling a positive shift in the company’s growth drivers.
Belanger also emphasizes that the sustained expansion of both Zynrelef and Aponvie will be critical to the company’s long-term trajectory, especially as legacy CINV products remain under pressure. He believes that the market is not fully recognizing the emerging contribution of these newer assets to Heron’s top line. As a result, he reiterates a Buy rating and a $3 price target, reflecting his view that the company’s growth potential, led by Zynrelef’s early success, is undervalued by investors.
According to TipRanks, Belanger is a 5-star analyst with an average return of 13.5% and a 51.10% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Cormedix, and Cytokinetics.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.